Center for Cancer Immune Therapy shared on LinkedIn:

“Molecular patterns of resistance to immune checkpoint blockade in melanoma.

Free access at Nature Communications (9 April 2024)

Key findings:

1. Molecular mechanisms explaining resistance may differ depending on immune checkpoint blockade (ICB) regimen,
2. PD1-resistant melanomas have few T cells, and in particular PD1+ tumor-reactive T cells,
3. Tertiary lymphoid structures are rare in ICB resistant melanomas.

Take home:

This study highlights the complexity of development of ICB resistance in melanoma.

Why it matters:

Understanding molecular mechanisms underlying ICB resistance can help identify new immunotherapeutic targets for patients in high need of treatment.

This study was conducted primarily at Lund University (group of Göran Jönsson) in close collaboration with Center for Cancer Immune Therapy (groups of Inge Marie Svane and Marco Donia).”

Source: Center for Cancer Immune Therapy/LinkedIn